Tazarotene
Other Antipsoriatics For Topical Use
Sold as ARAZLO · TAZORAC · DUOBRII
- Drug class
- Other Antipsoriatics For Topical Use
- Availability
- Prescription only
- Routes
- Cutaneous, Topical
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 54
Overview
Plain-language summary, compiled from the cited regulatory records
Tazarotene is a topical medication belonging to the drug class of other antipsoriatics for topical use [1]. It is approved for the treatment of plaque psoriasis and acne vulgaris [1]. Tazarotene is available under various brand names, including TAZORAC [1].
For plaque psoriasis, tazarotene cream is indicated for topical treatment in patients with this condition [1]. Additionally, tazarotene cream is approved for the topical treatment of acne vulgaris [1].
In the past 12 months, there have been 54 adverse event reports associated with tazarotene [2]. The most frequently reported reactions include diarrhea, the perception of the drug being ineffective, fatigue, a burning sensation, and constipation [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | November 13, 2025 |
| CA Canada | Health Canada | 2 | January 26, 2026 |
USUnited States· FDA
3 products
Uses
1% is a retinoid indicated for the topical treatment of plaque psoriasis. 1% is indicated for the topical treatment of acne vulgaris. 1% are indicated for the topical treatment of patients with plaque psoriasis. 1% is also indicated for the topical treatment of patients with acne vulgaris.
How to take
CACanada· Health Canada
2 products
Uses
ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established.
In a clinical pharmacokinetic study, systemic exposure of tazarotene and tazarotenic acid were substantially higher in subjects 10 to <12 years of age than subjects ≥12 years of age due to higher surface area to volume ratio of younger subjects.
Therefore, Health Canada recommends that application of ARAZLO in this age group be limited to the face (see 7 WARNINGS AND PRECAUTIONS; 10 ACTION AND CLINICAL PHARMACOLOGY; 14 CLINICAL TRIALS). Safety and efficacy of ARAZLO in children below the age of 10 years has not been established.
Therefore, Health Canada has not authorized an indication in pediatric patients less than 10 years of age. 4 Geriatrics).
Drug interactions
Known interactions involving Tazarotene. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 021744d1-a6d7-4a… · revised November 13, 2025 [PDF]
- [2]Health Canada (DPD) · 02517868 · revised January 26, 2026
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.